Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Medi & Gene is active in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These actions are assigned to 2 distinct examiners, showing that the company's current workload is split between different officials. Both of these matters are being handled within 1 distinct art unit, which indicates a high degree of technical concentration despite the involvement of multiple examiners.
ESPINOSA, CLAUDIA EDILMA is the busiest examiner for the portfolio, responsible for 1 busiest examiner pending office action. This 1 action is 1 of the 2 total pending office actions for the company. Because there are 2 distinct examiners working within the same 1 distinct art unit, practitioners can compare the different examination styles applied to similar technical subject matter. The strategy for resolving the 2 pending office actions should account for the specific preferences of ESPINOSA, CLAUDIA EDILMA.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ESPINOSA, CLAUDIA EDILMA | 1 | 50.9% | +57.7% |
| DABKOWSKI, ERINNE R | 1 | 55.9% | +69.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258578 | NOVEL PEPTIDE AND USE THEREOF | DABKOWSKI, ERINNE R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258577 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALCOHOLIC AND NONALCOHOLIC FATTY LIVER DISEASE | ESPINOSA, CLAUDIA EDILMA | 4d overdue |
| 18258578 | NOVEL PEPTIDE AND USE THEREOF | DABKOWSKI, ERINNE R | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18258577 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALCOHOLIC AND NONALCOHOLIC FATTY LIVER DISEASE | ESPINOSA, CLAUDIA EDILMA | 1654 | §103 | Final Rejection | 4d overdue | Pending | Jun 21, 2023 |
| 18258578 | NOVEL PEPTIDE AND USE THEREOF | DABKOWSKI, ERINNE R | 1654 | §101DP | Final Rejection | — | Pending | Jun 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial